| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 7758- | ISL, | Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications |
| - | Review, | Ovarian, | NA |
| 7760- | ISL, | Pharmacological Potentials and Delivery Strategies of Isoliquiritigenin: Challenges and Advances in Enhancing Bioavailability |
| - | Review, | Nor, | NA |
| 7761- | ISL, | Targeting digestive system cancers with isoliquiritigenin: a comprehensive review of antitumor mechanisms |
| - | Review, | Var, | NA |
| 7782- | ISL, | BUT, | SCP, | Butein, isoliquiritigenin, and scopoletin attenuate neurodegeneration via antioxidant enzymes and SIRT1/ADAM10 signaling pathway |
| - | in-vitro, | AD, | SH-SY5Y |
| 7780- | ISL, | Isoliquiritigenin alleviates LPS/ D-GalN-induced acute liver failure by activating the PGC-1α/ Nrf2 pathway to reduce oxidative stress and inflammatory response |
| - | in-vivo, | Nor, | NA |
| 7732- | isoFl, | Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity |
| 7730- | isoFl, | Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years |
| - | Review, | Var, | NA |
| 7866- | isoO, | Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects |
| - | Review, | Var, | NA |
| 7864- | isoO, | Isoorientin Inhibits Amyloid β25-35-Induced Neuronal Inflammation in BV2 Cells by Blocking the NF-κB Signaling Pathway |
| - | in-vitro, | AD, | BV2 |
| 7862- | isoO, | Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-κB signaling pathway in BV-2 microglia |
| - | in-vitro, | Nor, | BV2 |
| 7853- | isoO, | Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review |
| - | Review, | Var, | NA |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7856- | isoO, | Isoorientin induces the apoptosis and cell cycle arrest of A549 human lung cancer cells via the ROS‑regulated MAPK, STAT3 and NF‑κB signaling pathways |
| - | in-vitro, | Lung, | A549 |
| 7880- | isoO, | Inhibition of ROS-mediated activation Src-MAPK/AKT signaling by orientin alleviates H2O2-induced apoptosis in PC12 cells |
| - | in-vitro, | Nor, | PC12 |
| 7874- | isoO, | Isoorientin protects lipopolysaccharide-induced acute lung injury in mice via modulating Keap1/Nrf2-HO-1 and NLRP3 inflammasome pathways |
| - | in-vivo, | Nor, | NA |
| 7873- | isoO, | Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK, Akt, and Caspase-dependent signaling pathways |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Lung, | A549 |
| 7872- | isoO, | Isoorientin ameliorates H2O2-induced apoptosis and oxidative stress in chondrocytes by regulating MAPK and PI3K/Akt pathways |
| - | in-vivo, | Arthritis, | NA |
| 7795- | ISQ, | The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Nor, | HaCaT |
| 7823- | ISQ, | Isoquercitrin Upregulates Aldolase C Through Nrf2 to Ameliorate OGD/R-Induced Damage in SH-SY5Y Cells |
| - | in-vitro, | Stroke, | SH-SY5Y |
| 7813- | ISQ, | Isoquercitrin Played a Neuroprotective Role in Rats After Cerebral Ischemia/Reperfusion Through Up-Regulating Neuroglobin and Anti-Oxidative Stress |
| - | in-vivo, | Stroke, | NA |
| 7810- | ISQ, | Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7797- | ISQ, | Isoquercitrin Suppresses Esophageal Squamous Cell Carcinoma (ESCC) by Inducing Excessive Autophagy and Promoting Apoptosis via the AKT/mTOR Signaling Pathway |
| - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | ESCC, | KYSE450 |
| 7796- | ISQ, | Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway |
| - | vitro+vivo, | OS, | 143B | - | in-vitro, | OS, | U2OS |
| 7794- | ISQ, | Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 7838- | ISQ, | Protective effects of isoquercitrin on streptozotocin‐induced neurotoxicity |
| - | in-vivo, | AD, | NA |
| - | in-vitro, | AD, | HT22 |
| 8011- | itraC, | Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | SkBr3 |
| 8010- | itraC, | Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells |
| - | vitro+vivo, | GC, | MKN45 |
| 8012- | itraC, | Effects and mechanism of itraconazole on prostate cancer PC-3 cell apoptosis |
| - | in-vitro, | Pca, | PC3 |
| 7997- | itraC, | Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway |
| - | vitro+vivo, | SCC, | NA |
| 8039- | IVM, | Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy |
| - | NA, | neuroblastoma, | SH-SY5Y |
| 8038- | IVM, | Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction |
| - | in-vitro, | PC, | NA |
| 8035- | IVM, | Ivermectin and non-parasitic disorders: An update |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 8034- | IVM, | doxoR, | Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation |
| - | in-vitro, | Oral, | NA |
| 8032- | IVM, | Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids |
| - | in-vitro, | GC, | SNU620 | - | in-vitro, | GC, | SNU719 |
| 8029- | IVM, | Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? |
| - | Review, | Var, | NA |
| 8028- | IVM, | Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential |
| - | Review, | Var, | NA |
| 8027- | IVM, | Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin |
| - | Review, | Var, | NA |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8024- | IVM, | Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | NE3 |
| 8022- | IVM, | Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage |
| - | vitro+vivo, | RCC, | NA |
| 8050- | IVM, | doxoR, | Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma |
| - | in-vitro, | OS, | NA |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 1167- | IVM, | The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer |
| - | vitro+vivo, | NA, | NA |
| 7894- | IVT, | Isovitexin Inhibits Stemness and Induces Apoptosis in Hepatocellular Carcinoma SK-Hep-1 Spheroids by Upregulating miR-34a Expression |
| - | in-vitro, | HCC, | SK-HEP-1 |
| 7896- | IVT, | VT, | Molecular targets of vitexin and isovitexin in cancer therapy: a critical review |
| - | Review, | Var, | NA |
| 7895- | IVT, | Identification of Isovitexin as a novel CYP17A1 inhibitor through virtual screening and evaluation of its anti-cancer effects in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 7900- | IVT, | Isovitexin: A Promising Active Compound Found in Nature's Bounty |
| - | in-vivo, | Nor, | NA |
| 7901- | IVT, | Isovitexin restores sevoflurane‑induced cognitive dysfunction by mediating autophagy through activation of the PGC‑1α/FNDC5 signaling pathway |
| - | in-vivo, | Nor, | NA |
| 7903- | IVT, | Inhibition of advanced glycation end products by Isovitexin alleviates intestinal damage: Toward dietary strategies for gut health |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid